{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:34:32Z","timestamp":1790890472058,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40121-017-0156-z","type":"journal-article","created":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T14:24:51Z","timestamp":1491488691000},"page":"277-289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections"],"prefix":"10.1007","volume":"6","author":[{"given":"Cassie L.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy J.","family":"Frens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia B.","family":"Snider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,6]]},"reference":[{"issue":"Suppl 3","key":"156_CR1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1469-0691.2005.01138.x","volume":"11","author":"F Menichetti","year":"2005","unstructured":"Menichetti F. Current and emerging serious Gram-positive infections. Clin Microbiol Infect. 2005;11(Suppl 3):22\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"156_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","volume":"34","author":"DM Sievert","year":"2013","unstructured":"Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009\u20132010. Infect Control Hosp Epidemiol. 2013;34:1\u201314.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"156_CR3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","volume":"36","author":"SE Cosgrove","year":"2003","unstructured":"Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36:53\u20139.","journal-title":"Clin Infect Dis"},{"key":"156_CR4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","volume":"25","author":"SJ Hal van","year":"2012","unstructured":"van Hal SJ, Jensen SO, Vaska VL, et al. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev. 2012;25:362\u201386.","journal-title":"Clin Microbiol Rev"},{"key":"156_CR5","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18\u201355.","journal-title":"Clin Infect Dis"},{"key":"156_CR6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82\u201398.","journal-title":"Am J Health Syst Pharm"},{"key":"156_CR7","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1086\/420939","volume":"38","author":"AD Tice","year":"2004","unstructured":"Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis. 2004;38:1651\u201372.","journal-title":"Clin Infect Dis"},{"key":"156_CR8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","volume":"60","author":"GR Corey","year":"2015","unstructured":"Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of Gram-positive acute bacterial skin and skin structure infections: the SOLO II Noninferiority Study. Clin Infect Dis. 2015;60:254\u201362.","journal-title":"Clin Infect Dis."},{"key":"156_CR9","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1128\/AAC.03006-15","volume":"60","author":"JR Smith","year":"2016","unstructured":"Smith JR, Yim J, Raut A, et al. Oritavancin combinations with beta-lactams against multidrug-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Antimicrob Agents Chemother. 2016;60:2352\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"156_CR10","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1128\/AAC.00176-15","volume":"59","author":"CM Rubino","year":"2015","unstructured":"Rubino CM, Bhavnani SM, Moeck G, et al. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrob Agents Chemother. 2015;59:3365\u201372.","journal-title":"Antimicrob Agents Chemother"},{"key":"156_CR11","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1128\/AAC.00231-09","volume":"53","author":"CM Rubino","year":"2009","unstructured":"Rubino CM, Van Wart SA, Bhavnani SM, et al. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother. 2009;53:4422\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"156_CR12","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1128\/AAC.02482-13","volume":"58","author":"RE Mendes","year":"2014","unstructured":"Mendes RE, Sader HS, Flamm RK, et al. Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program. Antimicrob Agents Chemother. 2014;58:2921\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"156_CR13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.diagmicrobio.2016.07.025","volume":"86","author":"LR Duncan","year":"2016","unstructured":"Duncan LR, Sader HS, Flamm RK, et al. Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013\u20132014). Diagn Microbiol Infect Dis. 2016;86:303\u20136.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"156_CR14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/jac\/dks344","volume":"68","author":"I Morrissey","year":"2013","unstructured":"Morrissey I, Seifert H, Canton R, et al. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and beta-haemolytic streptococci collected from western European countries in 2011. J Antimicrob Chemother. 2013;68:164\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"156_CR15","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1128\/AAC.06067-11","volume":"56","author":"RE Mendes","year":"2012","unstructured":"Mendes RE, Woosley LN, Farrell DJ, et al. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009\u20132010. Antimicrob Agents Chemother. 2012;56:1639\u201342.","journal-title":"Antimicrob Agents Chemother"},{"key":"156_CR16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/03005368409078946","volume":"18","author":"JA Mellor","year":"1984","unstructured":"Mellor JA, Kingdom J, Cafferkey M, et al. Vancomycin ototoxicity in patients with normal renal function. Br J Audiol. 1984;18:179\u201380.","journal-title":"Br J Audiol"},{"key":"156_CR17","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1128\/AAC.00029-11","volume":"55","author":"LM Dunbar","year":"2011","unstructured":"Dunbar LM, Milata J, McClure T, et al. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother. 2011;55:3476\u201384.","journal-title":"Antimicrob Agents Chemother"},{"key":"156_CR18","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","volume":"370","author":"GR Corey","year":"2014","unstructured":"Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370:2180\u201390.","journal-title":"N Engl J Med"},{"key":"156_CR19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","volume":"60","author":"GR Corey","year":"2015","unstructured":"Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7\u201310\u00a0days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60:254\u201362.","journal-title":"Clin Infect Dis"},{"key":"156_CR20","doi-asserted-by":"crossref","first-page":"ofv156","DOI":"10.1093\/ofid\/ofv156","volume":"2","author":"JA Johnson","year":"2015","unstructured":"Johnson JA, Feeney ER, Kubiak DW, et al. Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis. Open Forum Infect Dis. 2015;2:ofv156.","journal-title":"Open Forum Infect Dis."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-017-0156-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T10:34:17Z","timestamp":1495794857000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-017-0156-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,6]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["156"],"URL":"https:\/\/doi.org\/10.1007\/s40121-017-0156-z","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,6]]}}}